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Movement disorders such as Parkinson’s disease and dyskinesia are highly debilitating
conditions linked to oxidative stress and neurodegeneration. When available,
the pharmacological therapies for these disorders are still mainly symptomatic,
do not benefit all patients and induce severe side effects. Cannabidiol is a
non-psychotomimetic compound from Cannabis sativa that presents antipsychotic,
anxiolytic, anti-inflammatory, and neuroprotective effects. Although the studies that
investigate the effects of this compound on movement disorders are surprisingly few,
cannabidiol emerges as a promising compound to treat and/or prevent them. Here,
we review these clinical and pre-clinical studies and draw attention to the potential of
cannabidiol in this field.
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CANNABIDIOL (CBD)
Cannabidiol (CBD) is one of the over 100 phytocannabinoids identified in Cannabis sativa (ElSohly
and Gul, 2014), and constitutes up to 40% of the plant’s extract, being the second most abundant
component (Grlic, 1976). CBD was first isolated from marijuana in 1940 by Adams et al. (1940)
and its structure was elucidated in 1963 by Mechoulam and Shvo (1963). Ten years later, Perez-
Reyes et al. (1973) reported that, unlike the main constituent of cannabis19-tetrahydrocannabinol
(19-THC), CBD does not induce psychological effects, leading to the suggestion that CBD was an
inactive drug. Nonetheless, subsequent studies demonstrated that CBDmodulates the effects of19-
THC and displays multiple actions in the central nervous system, including antiepileptic, anxiolytic
and antipsychotic effects (Zuardi, 2008).
Interestingly, CBD does not induce the cannabinoid tetrad, namely hypomotility, catalepsy,
hypothermia, and antinociception. In fact, CBD mitigates the cataleptic effect of 19-THC
(El-Alfy et al., 2010). Clinical and pre-clinical studies have pointed to beneficial effects of CBD on
the treatment of movement disorders. The first studies investigated CBD’s actions on dystonia,
with encouraging results. More recently, the studies have been focusing on Parkinson’s (PD)
and Huntington’s (HD) diseases. The mechanisms whereby CBD exerts its effects are still not
completely understood, mainly because several targets have been identified. Of note, CBD displays
anti-inflammatory and antioxidant actions (Campos et al., 2016), and both inflammation and
oxidative stress are linked to the pathogenesis of variousmovement disorders, such as PD (Farooqui
and Farooqui, 2011; Niranjan, 2014), HD (Sánchez-López et al., 2012), and tardive dyskinesia
(Zhang et al., 2007).
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It is noteworthy that, when available, the pharmacological
treatments for these movement disorders are mainly
symptomatic and induce significant side effects (Connolly
and Lang, 2014; Lerner et al., 2015; Dickey and La Spada, 2017).
Nonetheless, despite its great clinical relevance, the studies
evaluating CBD’s role on the pharmacotherapy of movement
disorders are surprisingly few. Here, we will review the clinical
and pre-clinical evidence and draw attention to the potential of
CBD in this field.
CBD’S MECHANISMS OF ACTION
CBD has several molecular targets, and new ones are currently
being uncovered. CBD antagonizes the action of CB1 and
CB2 receptors agonists, and is suggested to act as an inverse
agonist of these receptors (Pertwee, 2008). Moreover, recent
evidence point to CBD as a non-competitive negative allosteric
modulator of CB1 and CB2 (Laprairie et al., 2015; Martínez-
Pinilla et al., 2017). CBD is also an agonist of the vanilloid
receptor TRPV1 (Bisogno et al., 2001), and the previous
administration of a TRPV1 antagonist blocks some of CBD
effects (Long et al., 2006; Hassan et al., 2014). In parallel,
CBD inhibits the enzymatic hydrolysis and the uptake of
the main endocannabinoid anandamide (Bisogno et al., 2001),
an agonist of CB1, CB2 and TRPV1 receptors (Pertwee and
Ross, 2002; Ross, 2003). The increase in anandamide levels
induced by CBD seems to mediate some of its effects (Leweke
et al., 2012). Moreover, in some behavioral paradigms the
administration of an inhibitor of anandamide metabolism
promotes effects similar to CBD (Pedrazzi et al., 2015; Stern et al.,
2017).
CBD has also been shown to facilitate the neurotransmission
mediated by the serotonin receptor 5-HT1A. It was initially
suggested that CBD would act as an agonist of 5-HT1A (Russo
et al., 2005), but the latest reports propose that this interaction
might be allosteric or through an indirect mechanism (Rock
et al., 2012). Although this interaction is not fully elucidated,
multiple CBD’s effects were reported to depend on 5-HT1A
activation (Espejo-Porras et al., 2013; Gomes et al., 2013; Pazos
et al., 2013; Hind et al., 2016; Sartim et al., 2016; Lee et al.,
2017).
The peroxisome proliferator-activated receptor γ (PPARγ) is
a nuclear receptor involved in glucose metabolism and lipid
storage, and PPARγ ligands have been reported to display
anti-inflammatory actions (O’Sullivan et al., 2009). Data show
that CBD can activate this receptor (O’Sullivan et al., 2009),
and some of CBD effects are blocked by PPARγ antagonists
(Esposito et al., 2011; Dos-Santos-Pereira et al., 2016; Hind
et al., 2016). CBD also up-regulates PPARγ in a mice model
of multiple sclerosis, an effect suggested to mediate the CBD’s
anti-inflammatory actions (Giacoppo et al., 2017b). In a rat
model of Alzheimer’s disease, CBD, through interaction with
PPARγ, stimulates hippocampal neurogenesis, inhibits reactive
gliosis, induces a decline in pro-inflammatory molecules, and
consequently inhibits neurodegeneration (Esposito et al., 2011).
Moreover, in an in vitro model of the blood-brain barrier,
CBD reduces the ischemia-induced increased permeability
and VCAM-1 levels—both effects are attenuated by PPARγ
antagonism (Hind et al., 2016).
CBD also antagonizes the G-protein-coupled receptor GPR55
(Ryberg et al., 2007). GPR55 has been suggested as a
novel cannabinoid receptor (Ryberg et al., 2007), but this
classification is controversial (Ross, 2009). Currently, the
phospholipid lysophosphatidylinositol (LPI) is considered the
GPR55 endogenous ligand (Morales and Reggio, 2017). Although
only few studies link the CBD effect to its action on GPR55
(Kaplan et al., 2017), it is noteworthy that GPR55 has been
associated with PD in an animal model (Celorrio et al., 2017) and
with axon growth in vitro (Cherif et al., 2015).
More recently, CBD was reported to act as inverse agonist
of the G-protein-coupled orphan receptors GPR3, GPR6, and
GPR12 (Brown et al., 2017; Laun and Song, 2017). GPR6 has been
implicated in both HD and PD. Concerning animal models of
PD, GPR6 deficiency was related to both diminished dyskinesia
after 6-OHDA lesion (Oeckl et al., 2014), and increased sensitivity
to MPTP neurotoxicity (Oeckl and Ferger, 2016). Moreover,
Hodges et al. (2006) described decreased expression of GPR6 in
brain of HD patients, compared to control. GPR3 is suggested
as a biomarker for the prognosis of multiple sclerosis (Hecker
et al., 2011). In addition, GPR3, GPR6, and GPR12 have been
implicated in cell survival and neurite outgrow (Morales et al.,
2018).
CBD has also been reported to act on mitochondria.
Chronic and acute CBD administration increases the activity of
mitochondrial complexes (I, II, II-III, and IV), and of creatine
kinase in the brain of rats (Valvassori et al., 2013). In a rodent
model of iron overload—that induces pathological changes that
resemble neurodegenerative disorders—CBD reverses the iron-
induced epigenetic modification of mitochondrial DNA and
the reduction of succinate dehydrogenase’s activity (da Silva
et al., 2018). Of note, multiple studies associate mitochondrial
dysfunctions with the pathophysiology of PD (Ammal Kaidery
and Thomas, 2018).
In parallel, several studies show anti-inflammatory and
antioxidant actions of CBD (Campos et al., 2016). CBD treatment
decreases the levels of the pro-inflammatory cytokines IL-1β,
TNF-α, IFN-β, IFN-γ, IL-17, and IL-6 (Watzl et al., 1991; Weiss
et al., 2006; Esposito et al., 2007, 2011; Kozela et al., 2010; Chen
et al., 2016; Rajan et al., 2016; Giacoppo et al., 2017b), and
increases the levels of the anti-inflammatory cytokines IL-4 and
IL-10 (Weiss et al., 2006; Rajan et al., 2016). In addition, it
inhibits the expression of iNOS (Esposito et al., 2007; Pan et al.,
2009; Chen et al., 2016; Rajan et al., 2016) and COX-2 (Chen
et al., 2016) induced by distinct mechanisms. CBD also displays
antioxidant properties, being able to donate electrons under a
variable voltage potential and to prevent the hydroperoxide-
induced oxidative damage (Hampson et al., 1998). In rodent
models of PD and HD, CBD up-regulates the mRNA levels
of the antioxidant enzyme superoxide dismutase (Garcia-
Arencibia et al., 2007; Sagredo et al., 2007). In accordance, CBD
decreases oxidative parameters in in vitromodels of neurotoxicity
(Hampson et al., 1998; Iuvone et al., 2004; Mecha et al.,
2012). Of note, the anti-inflammatory and antioxidant effects of
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CBD on lipopolysaccharide-stimulated murine macrophages are
suppressed by a TRPV1 antagonist (Rajan et al., 2016). It has also
been shown that CBD can affect the expression of several genes
involved in zinc homeostasis, which is suggested to be linked
to its anti-inflammatory and antioxidant actions (Juknat et al.,
2012).
CBD’s mechanisms of action are summarized in Figure 1.
PARKINSON’S DISEASE (PD)
PD is among the most common neurodegenerative disorders,
with a prevalence that increases with age, affecting 1% of the
population over 60 years old (Tysnes and Storstein, 2017).
The disease is characterized by motor impairment (hypokinesia,
tremors, muscle rigidity) and non-motor symptoms (e.g., sleep
disturbances, cognitive deficits, anxiety, depression, psychotic
symptoms) (Klockgether, 2004).
The pathophysiology of PD is mainly associated with the loss
of midbrain dopaminergic neurons in the substantia nigra pars
compacta (SNpc), with consequent reduced levels of dopamine
in the striatum (Dauer and Przedborski, 2003). When the
motor symptoms appear, about 60% of dopaminergic neurons
is already lost (Dauer and Przedborski, 2003), hindering a
possible early diagnosis. The most effective and used treatment
for PD is L-DOPA, a precursor of dopamine that promotes an
increase in the level of dopamine in the striatum, improving
the motor symptoms (Connolly and Lang, 2014). However, after
a long-term treatment the effect of L-DOPA can be unstable,
presenting fluctuations in symptoms improvement (on / off
effect) (Jankovic, 2005; Connolly and Lang, 2014). In addition,
involuntary movements (namely L-DOPA-induced dyskinesia)
appear in approximately 50% of the patients (Jankovic, 2005).
The first study with CBD on PD patients aimed to verify
CBD’s effects on the psychotic symptoms. Treatment with
CBD for 4 weeks decreased the psychotic symptoms, evaluated
by the Brief Psychiatric Rating Scale and the Parkinson
Psychosis Questionnaire, without worsening the motor function
or inducing adverse effects (Zuardi et al., 2009). Later, in a
case series with four PD patients, it was verified that CBD
is able to reduce the frequency of the events related to REM
sleep behavior disorder (Chagas et al., 2014a). In addition,
although not ameliorating PD patients’ motor function or their
general symptoms score, treatment with CBD for 6 weeks
improves PD’s patients quality of life (Chagas et al., 2014b).
The authors suggest that this effect might be related to CBD’s
anxiolytic, antidepressant and antipsychotic properties (Chagas
et al., 2014b).
Although the studies with patients with PD report beneficial
effects of CBD only on the non-motor symptoms, CBD has
been shown to prevent and/or reverse increased catalepsy
behavior in rodents. When administered before the cataleptic
agents haloperidol (antipsychotic drug), L-nitro-N-arginine
(non-selective inhibitor of nitric oxide synthase) or WIN 55-
212,2 (agonist of cannabinoid receptors), CBD hinders the
cataleptic behavior in a dose-dependent manner (Gomes et al.,
2013). A possible role of the activation of serotonin receptors
5-HT1A in this action has been proposed, because this effect of
CBD is blocked by the pre-treatment with the 5-HT1A antagonist
FIGURE 1 | CBD’s mechanisms of action. CBD acts as agonist of the receptors TRPV1, PPARγ, and 5-HT1A, and as antagonist of the receptor GPR55. CBD is an
inverse agonist of the receptors GPR3, GPR6, and GPR12. Moreover, CBD antagonizes the action of CB1 and CB2 receptors agonists, and is suggested to act as an
inverse agonist and a negative allosteric modulator of these receptors. CBD also inhibits FAAH, which results in increased anandamide levels. Anandamide activates
CB1, CB2, and TRPV1 receptors. By acting on mitochondria, CBD increases the activity of mitochondrial complexes. In addition, CBD displays antioxidant and
anti-inflammatory effects—that are partially mediated by CBD’s actions on TRPV1, mitochondria and PPARγ. 5-HT1A, serotonin receptor 1A; CB1, cannabinoid
receptor type 1; CB2, cannabinoid receptor type 2; FAAH, fatty acid amide hydrolase; GPR3, G-protein-coupled receptor 3; GPR6, G-protein-coupled receptor 6;
GPR12, G-protein-coupled receptor 12; GPR55, G-protein-coupled receptor 55; PPARγ, peroxisome proliferator-activated receptor gamma; ROS, reactive oxygen
species; TRPV1, transient receptor potential vanilloid type 1.
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WAY100635 (Gomes et al., 2013). In accordance, Sonego et al.
(2016) showed that CBD diminishes the haloperidol-induced
catalepsy and c-Fos protein expression in the dorsal striatum,
also by amechanism dependent on 5-HT1A activation. Moreover,
CBD prevents the increased catalepsy behavior induced by
repeated administration of reserpine (Peres et al., 2016).
In addition, pre-clinical studies in animal models of PD have
shown neuroprotective effects of CBD. The unilateral injection
of the toxin 6-hydroxydopamine (6-OHDA) into the medial
forebrain bundle promotes neurodegeneration of nigrostriatal
dopaminergic neurons, being used to model PD (Bové et al.,
2005). When inside the cell, the neurotoxin 6-OHDA oxidizes
in hydrogen peroxide and paraquinone, causing death mainly of
catecolaminergic neurons (Breese and Traylor, 1971; Bové et al.,
2005). This neurodegeneration leads to depletion of dopamine
and decrease in tyrosine hydroxylase activity in caudate-putamen
(Bové et al., 2005; Lastres-Becker et al., 2005). Treatment with
CBD during the 2 weeks following 6-OHDA administration
prevents these effects (Lastres-Becker et al., 2005). In another
study, it was observed that CBD’s protective effects after 6-OHDA
injury are accompanied by elevation of mRNA levels of the
antioxidant enzyme Cu,Zn-superoxide dismutase in substantia
nigra (Garcia-Arencibia et al., 2007). The protective effects of
CBD in this model do not seem to depend on the activation
of CB1 receptors (Garcia-Arencibia et al., 2007). In addition
to preventing the loss of dopaminergic neurons—assessed by
tyrosine hydroxylase immunostaining –, the administration of
CBD after 6-OHDA injury attenuates the activation of microglia
in substantia nigra (Garcia et al., 2011).
In an in vitro study, CBD increased the viability of
cells treated with the neurotoxin N-methyl-4-phenylpyrimidine
(MPP+), and prevented the MPP+-induced increase in caspase-
3 activation and decrease in levels of nerve growth factor (NGF)
(Santos et al., 2015). CBD treatment was also able to induce
cell differentiation even in the presence of MPP+, an effect
that depends on trkA receptors (Santos et al., 2015). MPP+
is a product of oxidation of MPTP that inhibits complex I of
the respiratory chain in dopaminergic neurons, causing a rapid
neuronal death (Schapira et al., 1990; Meredith et al., 2008).
Data from clinical and pre-clinical studies are summarized in
Tables 1, 2, respectively.
HUNTINGTON’S DISEASE (HD)
HD is a fatal progressive neurodegenerative disease characterized
by motor dysfunctions, cognitive loss and psychiatric
manifestations (McColgan and Tabrizi, 2018). HD is caused
by the inclusion of trinucleotides (CAG) in the exons of the
huntingtin gene, on chromosome 4 (MacDonald et al., 1993;
McColgan and Tabrizi, 2018), and its prevalence is 1–10,000
(McColgan and Tabrizi, 2018). Neurodegeneration in HD affects
mainly the striatal region (caudate and putamen) and this
neuronal loss is responsible for the motor symptoms (McColgan
and Tabrizi, 2018). Cortical degeneration is seen in later stages,
and huntingtin inclusions are seen in few cells, but in all patients
with HD (Crook and Housman, 2011). The diagnosis of HD is
based on motor signs accompanied by genetic evidence, which is
positive genetic test for the expansion of the huntingtin gene or
family history (Mason and Barker, 2016; McColgan and Tabrizi,
2018).
The pharmacotherapy of HD is still directed toward the
symptomatic relief of the disease, i.e., the motor disorders
believed to be due to dopaminergic hyperactivity. This treatment
is often conducted with typical and atypical antipsychotics, but
in some cases the use of dopaminergic agonists is needed (Mason
and Barker, 2016; McColgan and Tabrizi, 2018). Indeed, the role
of dopamine in HD is not fully elucidated yet. Regarding the
cognitive deficits, none of the investigated drugs was able to
promote improvements (Mason and Barker, 2016;McColgan and
Tabrizi, 2018).
Recently, there has been a growing number of studies aiming
to verify the therapeutic potential of cannabinoid compounds in
the treatment of HD, mainly because some cannabinoids present
hypokinetic characteristics (Lastres-Becker et al., 2002). In a
controlled clinical trial, patients with HD were treated with CBD
for 6 weeks. There was no significant reduction in the chorea
indicators, but no toxicity was observed (Consroe et al., 1991).
The protective effects of CBD and other cannabinoids were
also evaluated in a cell culture model of HD, with cells expressing
mutated huntingtin. In this model, the induction of huntingtin
promotes rapid and extensive cell death (Aiken et al., 2004).
CBD and the other three cannabinoid compounds tested—
1
8-THC, 19-THC, and cannabinol—show 51–84% protection
against the huntingtin-induced cell death (Aiken et al., 2004).
These effects seem to be independent of CB1 activation, since
absence of CB1 receptors has been reported in PC12, the cell
line used (Molderings et al., 2002). The authors suggest that
the cannabinoids exert this protective effect by antioxidant
mechanisms (Aiken et al., 2004).
Regarding studies with animal models, treatment with 3-
nitropropionic acid (3-NP), an inhibitor of complex II of the
respiratory chain, induces striatal damage—mainly by calpain
activation and oxidative injury –, being suggested as relevant
to study HD (Brouillet et al., 2005). Sub-chronic administration
of 3-NP in rats reduces GABA contents and the levels of
mRNA for several markers of striatal GABAergic neurons
projections (Sagredo et al., 2007). In addition, 3-NP diminishes
the levels of mRNA for the antioxidant enzymes superoxide
dismutase-1 (SOD-1) and -2 (SOD-2) (Sagredo et al., 2007).
The administration of CBD reverses or attenuates these 3-NP-
induced alterations (Sagredo et al., 2007). CBD’s neuroprotective
effects are not blocked by the administration of antagonists of the
CB1, TRPV1 or A2A receptors (Sagredo et al., 2007).
More recently, clinical and pre-clinical HD studies started to
investigate the effects of Sativex R© (CBD in combination with
1
9-THC in an approximately 1:1 ratio). In accordance with
what previously seen with CBD alone, Sativex administration
attenuates all the 3-NP induced neurochemical, histological and
molecular alterations (Sagredo et al., 2011). These effects do not
seem to be linked to activation of CB1 or CB2 receptors (Sagredo
et al., 2011). Authors also observed a protective effect of Sativex
in reducing the increased expression of iNOS gene induced by
malonate (Sagredo et al., 2011). Malonate administration leads to
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TABLE 1 | Clinical studies investigating the effects of CBD on movement disorders.
Disease Main Findings Duration of
Treatment
Dose of CBD and route of
administration
Patients characteristics References
PD Open-label pilot study. Treatment with
CBD for 4 weeks diminished the psychotic
symptoms. CBD did not worsen the motor
function or induce adverse effects.
4 weeks 150 mg/day of CBD, increasing
by 150mg every week,
depending on patients’ clinical
response. Oral route.
6 PD patients (4 men and 2
women) with psychosis—not
controlled with reduction of
antiparkinsonian
medications—for at least 3
months before the beginning of
the study. Patients were in stable
doses of anti-PD medication for
at least 7 days.
Zuardi et al., 2009
PD Case series. CBD reduced the frequency
of the events related to REM sleep
behavior disorder.
6 weeks 75 mg/day (3 patients) or 300
mg/day (1 patient) of CBD. Oral
route.
4 PD male patients with REM
sleep behavior disorder, with at
least two episodes of complex
sleep-related behaviors per
week.
Chagas et al., 2014a
PD Exploratory double-blind trial. Treatment
with CBD did not improve the motor
function or the general symptoms score,
but the higher dose (300 mg/kg) improved
quality of life.
6 weeks 75 or 300 mg/day of CBD. Oral
route.
21 PD patients (15 men and 6
women) in stable doses of
anti-PD medication for at least
30 days before the beginning of
the study.
Chagas et al., 2014b
HD Controlled clinical trial (double-blind
randomized crossover). Treatment with
CBD did not improve the symptoms, but it
was not toxic.
6 weeks 10 mg/kg/day of CBD. Oral
route.
15 patients (8 men and 7
women) with mild or moderate
progression of HD, not taking
antipsychotic drugs for at least 2
weeks before the beginning of
the study.
Consroe et al., 1991
HD Double-blind, randomized, cross-over,
placebo-controlled, pilot trial. Sativex did
not induce severe adverse effects or
clinical worsening. However, Sativex did
not improve patients’ symptoms or
promoted molecular changes on
biomarkers.
12 weeks Increasing doses of Sativex
(CBD:THC in approximately 1:1
ratio) up to 12 sprays/day.
Intranasal route.
25 HD (14 men and 11 women)
patients with stable baseline
medication for at least 6 weeks
before the beginning of the study.
López-Sendón Moreno
et al., 2016
HD Case report of HD patients treated with
cannabinoid. Cannabinoids improved
UHDRS motor score and dystonia
subscore.
6 or 9 months Sativex: 12 or 7 sprays/day.
Intranasal route.
2 male HD patients with
complains of severe dystonia.
Duration of the disease: 14 and
16 years.
Saft et al., 2018
Dystonic
movement
disorders
Open label study. Treatment with CBD
resulted on 20–50% improvement of the
dystonic symptoms. Two patients with
simultaneous PD’s signs showed
worsening of their hypokinesia and/or
resting tremor when receiving the higher
doses of CBD (over 300 mg/day).
6 weeks Increasing doses of CBD from
100 to 600 mg/day. Oral route.
5 patients (4 men and 1 woman)
with dystonic movements, 2 with
simultaneous parkinsonian
symptoms.
Consroe et al., 1986
Dystonic
movement
disorders
Case report. CBD improved the dystonic
symptoms without inducing adverse
effects.
One
administration
CBD 200mg. Oral route. 2 patients: one woman with
idiopathic spasmodic torticollis
and one man with generalized
torsion dystonia.
Sandyk et al., 1986
CBD, cannabidiol; HD, Huntington’s disease; PD, Parkinson’s disease; REM, rapid-eye movement; THC, 19-tetrahydrocannabinol.
striatal damage by apoptosis and inflammatory events related to
glial activation, being used as an acute model for HD (Sagredo
et al., 2011; Valdeolivas et al., 2012).
In a subsequent study, it was observed that the administration
of a Sativex-like combination attenuates all the malonate-
induced alterations, namely: increased edema, decreased number
of surviving cells, enhanced number of degenerating cells,
strong glial activation, and increased expression of inflammatory
markers (iNOS and IGF-1) (Valdeolivas et al., 2012). Although
the beneficial effects of Sativex on cell survival are blocked by
both CB1 or CB2 antagonists, CB2 receptors seem to have a
greater role in the protective effect observed (Valdeolivas et al.,
2012).
The beneficial effects of Sativex have also been described
in the R6/2 mice, a transgenic model of HD. Treatment with
a Sativex-like combination, although not reversing animal’s
deterioration in rotarod performance, attenuates the elevated
clasping behavior, that reflects dystonia (Valdeolivas et al., 2017).
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TABLE 2 | Pre-clinical studies investigating the effects of CBD on movement disorders.
Model Main findings References
Hamster model of idiopathic paroxysmal
dystonia
The higher dose of CBD shows a trend to delay the progression of dystonia. Richter and Loscher, 2002
PC12 cells expressing mutated huntingtin CBD and the other three cannabinoid compounds tested—18-THC, 19-THC, and
cannabinol—show 51–84% protection against the huntingtin-induced cell death. These
protective effects seem to be independent of CB1 receptors.
Aiken et al., 2004
Rats lesioned by the toxin 6-OHDA Treatment with CBD for 2 weeks subsequent to lesion by the toxin 6-OHDA prevents the
6-OHDA-induced depletion of dopamine and decrease in tyrosine hydroxylase activity in
caudate-putamen.
Lastres-Becker et al., 2005
Rats lesioned by the toxin 6-OHDA Treatment with CBD for 2 weeks subsequent to lesion by 6-OHDA prevents the
6-OHDA-induced depletion of dopamine and decrease in tyrosine hydroxylase activity in
caudate-putamen. CBD promoted upregulation of mRNA levels for the antioxidant
enzyme Cu,Zn-superoxide dismutase. These protective effects do not seem to depend on
activation of CB1 receptors.
Garcia-Arencibia et al., 2007
Rats treated with 3-nitropropionic acid
(3-NP)
Sub-chronic administration of 3-NP reduces GABA contents, levels of mRNA for several
markers of striatal GABAergic neurons projections, and the levels of mRNA for the
antioxidant enzymes superoxide dismutase-1 (SOD-1) and−2 (SOD-2). CBD reverses or
attenuates the 3-NP-induced alterations. CBD’s neuroprotective effects are not blocked
by antagonists of the CB1, TRPV1 or A2A receptors.
Sagredo et al., 2007
Rats lesioned by the toxin 6-OHDA Treatment with CBD for 2 weeks subsequent to lesion by 6-OHDA prevents the
6-OHDA-induced decrease in tyrosine hydroxylase immunostaining, as well as enhanced
microglial activation in the substantia nigra.
Garcia et al., 2011
Rats treated with 3-nitropropionic acid
(3-NP) or malonate
Sub-chronic administration of 3-NP reduces GABA contents, diminishes the number of
Nissl-stained neurons, down-regulates the expression of CB1 receptor and IGF-1,
up-regulates the expression of calpain, and reduces the expression of superoxide
dismutase-1 (SOD-1). Sativex (CBD and 19-THC in an approximately 1:1 ratio) attenuates
all the 3-NP-induced alterations. This effect is not blocked by antagonists of CB1 or CB2
receptors. In addition, rats treated with malonate display increased expression of the iNOS
gene, reversed by the administration of Sativex.
Sagredo et al., 2011
Rats treated with malonate Malonate increases edema, decreases the number of surviving cells, enhances the
number of degenerating cells, induces strong glial activation, and increases the expression
of the inflammatory markers iNOS and IGF-1. Sativex-like combination attenuates all
malonate-induced alterations. Sativex effect seems to depend on both CB1 and CB2
receptors.
Valdeolivas et al., 2012
Mice injected with cataleptic agents Pre-treatment with CBD dose-dependently attenuates the increase in catalepsy behavior
induced by haloperidol, L-nitro-N-arginine or WIN 55,212-2. CBD’s anticataleptic effect is
prevented by the administration of WAY100635 (antagonist of 5-HT1A receptors).
Gomes et al., 2013
PC12 cells treated with the toxin MPP+ CBD increases cell viability and prevents the MPP+-induced increase in caspase-3
activation and decrease in levels of NGF. CBD treatment also induces cell differentiation
even in the presence of MPP+. CBD’s effects on neuritogenesis seem to depend on trkA
receptors.
Santos et al., 2015
Mice treated with L-DOPA CBD, when administered with capsazepine, an antagonist of TRPV1 receptors, decreases
L-DOPA-induced dyskinesia. These effects are blocked by antagonists of CB1 and PPARγ
receptors. Treatment with capsazepine and CBD also decreases the expression of
inflammatory markers (COX-2 and NFkB).
Dos-Santos-Pereira et al.,
2016
Rats injected with the cataleptic and
dyskinesia-inducing agent reserpine
Repeated administration of reserpine induces catalepsy, hypolocomotion, oral dyskinesia
and impairment in the discriminative avoidance memory task. Concomitant treatment with
CBD prevents the increase in catalepsy behavior, the oral dyskinesia and the memory
deficit.
Peres et al., 2016
Mice injected with the cataleptic agent
haloperidol
CBD prevents haloperidol-induced catalepsy and increase in c-Fos protein expression in
the dorsolateral striatum. CBD also reverses the increase in catalepsy behavior induced by
haloperidol. These CBD effects are prevented by the administration of WAY100635
(antagonist of 5-HT1A receptors). CBD’s anticataleptic effect is also observed when CBD
is injected into the dorsal striatum.
Sonego et al., 2016
R6/2 mice (transgenic mouse models of
HD)
Treatment with Sativex-like combination (from 4th to 12th weeks after birth) attenuated the
R6/2 mice increased clasping behavior (that reflects dystonia) and reduced metabolic
activity in basal ganglia. Sativex also reversed some of animals’ alterations in markers of
brain integrity, but not the deterioration in rotarod performance.
Valdeolivas et al., 2017
1
8-THC, 18-tetrahydrocannabinol; 19-THC, 19-tetrahydrocannabinol; 3-NP, 3-nitropropionic acid; 6-OHDA, 6-hydroxydopamine; CBD, cannabidiol; HD, Huntington’s disease; IGF-1,
insulin growth factor 1; iNOS, inducible nitric oxide synthase; MPP+, 1-methyl-4-phenylpyridinium; NGF, nerve growth factor; PD, Parkinson’s disease; SOD, superoxide dismutase.
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Moreover, treatment mitigates R6/2 mice reduced metabolic
activity in basal ganglia and some of the alterations in markers
of brain integrity (Valdeolivas et al., 2017).
In spite of the pre-clinical encouraging results with Sativex,
a pilot trial with 25 HD patients treated with Sativex for 12
weeks failed to detect improvement in symptoms or molecular
changes on biomarkers (López-Sendón Moreno et al., 2016).
Nonetheless, Sativex did not induce severe adverse effects or
clinical worsening (López-Sendón Moreno et al., 2016). The
authors suggest that future studies, with higher doses and/or
longer treatment periods, are in need. More recently, one study
described the results of administering cannabinoid drugs to 7
patients (2 of them were treated with Sativex; the others received
dronabinol or nabilone, agonists of the cannabinoid receptors):
patients displayed improvement on UHDRS motor score and
dystonia subscore (Saft et al., 2018).
Tables 1, 2 summarize data from clinical and pre-clinical
studies, respectively.
OTHER MOVEMENT DISORDERS
Dystonias are the result of abnormal muscles tone, causing
involuntary muscle contraction, and resulting in repetitive
movements or abnormal posture (Breakefield et al., 2008).
Dystonias can be primary, for instance paroxysmal dyskinesia,
or secondary to other conditions or drug use, such as tardive
dyskinesia after prolonged treatment with antipsychotic drugs
(Breakefield et al., 2008).
Consroe et al. (1986) were the first to evaluate the effects
of CBD alone in movement disorders. In this open label study,
the five patients with dystonic movement disorders displayed
20–50% improvement of dystonic symptoms when treated with
CBD for 6 weeks. Of note, two patients with simultaneous PD’s
signs showed worsening of their hypokinesia and/or resting
tremor when receiving the higher doses of CBD. However,
it should be noted that in two more recent studies with PD
patients no worsening of motor function was seen (Zuardi
et al., 2009; Chagas et al., 2014b). In accordance, Sandyk
et al. (1986) reported improvement of dystonic symptoms in
two patients—one with idiopathic spasmodic torticollis and
one with generalized torsion dystonia—after acute treatment
with CBD.
The effects of CBD on dystonic movements were also
evaluated in pre-clinical studies. In a hamster model of
idiopathic paroxysmal dystonia, the higher dose of CBD
showed a trend to delay the progression of dystonia (Richter
and Loscher, 2002). In addition, CBD prevents the increase
in vacuous chewing movements, i.e., dyskinesia, promoted
by repeated administration of reserpine (Peres et al., 2016).
CBD’s beneficial effects are also seen in L-DOPA-induced
dyskinesia in rodents, but only when CBD is administered
with capsazepine, an antagonist of TRPV1 receptors (Dos-
Santos-Pereira et al., 2016). These effects seem to depend on
CB1 and PPARγ receptors (Dos-Santos-Pereira et al., 2016). In
addition, treatment with capsazepine and CBD decreases the
expression of inflammatory markers, reinforcing the suggestion
that the anti-inflammatory actions of CBD may be beneficial
to the treatment of dyskinesia (Dos-Santos-Pereira et al.,
2016).
Moreover, Sativex has been used in the treatment of
spasticity in multiple sclerosis. Spasticity is a symptom that
affects up to 80% of patients with multiple sclerosis and is
associated with poorer quality of life (Flachenecker et al.,
2014). A significant portion of patients does not respond to
the conventional anti-spasmodic therapies, and some strategies
are invasive, posing risks of complications (Flachenecker et al.,
2014; Crabtree-Hartman, 2018). Recent data point to Sativex
as a valid and well-tolerated therapeutic option. Sativex is
able to treat the spasms, improving the quality of life, and
displays a low incidence of adverse effects (Giacoppo et al.,
2017a).
Data from clinical and pre-clinical studies are summarized in
Tables 1, 2, respectively.
SAFETY AND SIDE EFFECTS
One important concern is whether CBD is a safe therapeutic
strategy. Several preclinical and clinical reports show that CBD
does not alter metabolic and physiological parameters, such
as glycemia, prolactin levels, blood pressure, and heart rate.
In addition, CBD does not modify hematocrit, leukocyte and
erythrocyte counts, and blood levels of bilirubin and creatinine
in humans. CBD also does not affect urine osmolarity, pH,
albumin levels, and leukocyte and erythrocyte counts. Moreover,
in vitro studies demonstrate that CBD does not alter embryonic
development nor the vitality of non-tumor cell lines. The most
reported side effects of CBD are tiredness, diarrhea, and changes
on appetite. CBD does not seem to induce tolerance. For a broad
review of CBD’s side effects, see Bergamaschi et al. (2011) and
Iffland and Grotenhermen (2017).
In the context of movement disorders with concomitant
cognitive symptoms, as the ones discussed here, it is crucial
to evaluate the potential motor and cognitive side effects of
CBD. CBD does not induce catalepsy behavior in rodents—being
even able to attenuate the effects of several cataleptic agents, as
discussed above (El-Alfy et al., 2010; Gomes et al., 2013; Peres
et al., 2016; Sonego et al., 2016). In accordance, CBD does not
induce extrapyramidal effects in humans (Leweke et al., 2012).
With respect to cognitive effects, studies report that CBD does
not impair cognition, being even able to improve it in some
conditions. Pre-clinical data show that CBD restores the deficit
in the novel object recognition task in mice treated with MK-801
(a protocol used to model schizophrenia) (Gomes et al., 2015), in
rats submitted to neonatal iron overload (Fagherazzi et al., 2012),
in a transgenic mice model for Alzheimer’s disease (Cheng et al.,
2014), and in a mice model for cerebral malaria (Campos et al.,
2015). CBD also reverses impaired social recognition in a murine
model for Alzheimer’s disease (Cheng et al., 2014) and restores
the deficits in the Morris water maze—a task that evaluates
spatial learning—in rodent models for Alzheimer’s disease
(Martín-Moreno et al., 2011), brain ischemia (Schiavon et al.,
2014) and cerebral malaria (Campos et al., 2015). In addition,
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studies demonstrate that CBD per se does not modify animals’
performance in cognitive tasks (Osborne et al., 2017; Myers et al.,
2018) and does not induce withdrawal after prolonged treatment
(Myers et al., 2018). In accordance, in one recent clinical
trial using CBD as an adjunctive therapy for schizophrenia,
CBD group displayed greater cognitive improvement (assessed
by BACS—Brief Assessment of Cognition in Schizophrenia),
although it fell short of significance (McGuire et al., 2018).
CBD also improves facial emotion recognition in cannabis users
(Hindocha et al., 2015).
It is noteworthy that in some cases, particularly concerning
multiple sclerosis and HD clinical studies, CBD per se does
not seem to be beneficial. However, when CBD is administered
with 19-THC in a 1:1 ratio, therapeutic effects are observed.
Therefore, it is also important to evaluate the interactions
between CBD and 19-THC as well as the adverse effects of
this mixture. Multiple reports point to deleterious effects of 19-
THC on human cognition, mainly on memory and emotional
processing (Colizzi and Bhattacharyya, 2017). On the other hand,
studies reveal that CBD can counteract 19-THC detrimental
cognitive effects in rodents and monkeys (Wright et al., 2013;
Jacobs et al., 2016; Murphy et al., 2017). Nonetheless, this
protective effect depends on the doses, on the interval between
CBD and 19-THC administration, as well as on the behavioral
paradigm used. In fact, some pre-clinical studies do not observe
the protective effect of CBD against the19-THC cognitive effects
(Wright et al., 2013; Jacobs et al., 2016) or even show that CBD
may potentiate them (Hayakawa et al., 2008). Limited clinical
evidence indicate that CBD does not worse 19-THC cognitive
effects and, depending on the dose, may protect against them
(Colizzi and Bhattacharyya, 2017; Englund et al., 2017; Osborne
et al., 2017). Multiple clinical studies with Sativex have not
observed motor or cognitive adverse effects (Aragona et al.,
2009; Rekand, 2014; López-Sendón Moreno et al., 2016; Russo
et al., 2016). Nevertheless, one recent open-label study compared
multiple sclerosis patients who continued the treatment with
Sativex to those who quitted and reported worse balance and
decrease in cognitive performance in the continuers (Castelli
et al., 2018). In line with these findings, in an observational study
with a large population of Italian patients with multiple sclerosis,
cognitive/psychiatric disturbances were seen in 3.9% of the cases
(Patti et al., 2016).
CONCLUSIONS
The data reviewed here point to a protective role of CBD in
the treatment and/or prevention of some movement disorders.
Although the studies are scarce, CBD seems to be effective on
treating dystonic movements, both primary and secondary. It is
noteworthy that in some cases, particularly concerning multiple
sclerosis and HD, the clinical beneficial effects are observed only
when CBD is combined with 19-THC in a 1:1 ratio (Sativex).
In fact, these therapeutic effects are probably due to 19-THC,
since they are also seen with other cannabinoid agonists (Curtis
et al., 2009; Nielsen et al., 2018; Saft et al., 2018). Nonetheless,
CBD is shown to diminish the 19-THC unwanted effects, such
as sedation, memory impairments, and psychosis (Russo and
Guy, 2006). Data regarding HD are scarce, but the results of
using Sativex in multiple sclerosis are encouraging. Reviews of
the clinical use of this compound in the last decade point to
effectiveness in the treatment of spasticity as well as improvement
in quality of life, with low incidence of adverse effects (Giacoppo
et al., 2017a).
In respect to PD, although the pre-clinical studies are
promising, the few studies with patients failed to detect
improvement of the motor symptoms after treatment with CBD.
There is a significant difference between the clinical and pre-
clinical PD studies. In animals, the beneficial effects are seen
when CBD is administered prior to or immediately after the
manipulation that induces the PD-like symptoms. Of note, when
treatment with CBD commences 1 week after the lesion with
6-OHDA, the protective effects are not seen (Garcia-Arencibia
et al., 2007). These data suggest that CBD’s might have a
preventive role rather than a therapeutic one in PD. In clinical
practice, PD is diagnosed subsequently to the emergence of
motor symptoms—that appear up to 10 years after the beginning
of neurodegeneration and the onset of non-motor symptoms
(Schrag et al., 2015). When the diagnosis occur, approximately
60% of the dopaminergic neurons has already been lost (Dauer
and Przedborski, 2003). The fact that in clinical trials CBD is
administered only after this substantial progression of the disease
might explain the conflicting results. Unfortunately, the early
diagnosis of PD remains a challenge, posing difficulty to the
implementation of preventive strategies. The development of
diagnosis criteria able to detect PD in early stages would probably
expand the CBD’s applications in this disease.
The molecular mechanisms associated with CBD’s
improvement of motor disorders are likely multifaceted.
Data show that it might depend on CBD’s actions on 5-HT1A,
CB1, CB2, and/or PPARγ receptors. Moreover, all movement
disorders are in some extent linked to oxidative stress and
inflammation, and CBD has been reported to display an
antioxidant and anti-inflammatory profile, in vitro and in animal
models for movement abnormalities.
The studies investigating the role of CBD on the treatment
of movement disorders are few. Furthermore, differences in
the dose and duration of treatment as well as in the stage
of the disease (for instance, PD patients are treated only
in an advanced stage of the disease) among these studies
(shown in detail in Table 1) limit the generalization of the
positive effect of CBD and might explain the conflicting results.
Notwithstanding, the beneficial neuroprotective profile of CBD
added to the preliminary results described here are encouraging.
Undoubtedly, future investigations are needed to endorse these
initial data and to elucidate the mechanisms involved in the
preventive and/or therapeutic potential of CBD on movement
disorders.
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